Chronic Heart Failure and Cytokines
Keywords:
Chronic heart failure, cytokines, TGF-β1, cardiac fibrosis, hypertrophy
Abstract
Chronic heart failure (CHF) is considered as a global non-communicable pandemic. In the pathogenesis of CHF, many factors are considered, including inflammatory cytokines. Cytokines is a group of soluble peptide mediators of the immune system, which is necessary for its development, functioning and interaction with other body systems.
TGF-β1 is a member of the group of multifocal cytokines. Many studies have shown the roles of TGF-β1 activation in the development of CVD, such as hypertension, cardiac hypertrophy and cardiac fibrosis leading to heart failure, as well as restenosis after coronary intervention and atherosclerosis. An analysis of the results of the studies performed indicates the direct involvement of TGF-β1 and its genetic structure in the processes of myocardial remodeling in heart failure, and also substantiates the need for further research in this direction.
References
1. Аляви А.Л., Камилова У.К., Расулова З.Д. Диагностика и лечение хронической сердечной недостаточности. // Монография. – 2016. – 196 c
2. Emelia J. Benjamin, Paul Muntner, Alvaro Alonso et.al. Heart Disease and Stroke Statistics – 2019 Update: American Association. Report From Heart https://doi.org/10.1161/CIR.0000000000000659. Circulation. 2019. Vol 139. No 10:e56–e528.).
3. Токмачев Р.Е., Будневский А.В., Кравченко А.Я. Роль воспаления в патогенезе хронической сердечной недостаточности. Терапевтический архив. 2016;88(9):106 110.
4. ВолковаС.Ю. Диагностические возможности ряда нейрогуморальных систем в определении систолической дисфункции левого желудочка у боль-ных ИБС с сердечной недостаточно-стью // Журнал Сер-дечная Недостаточность. –2008. –Т. 9, No1 (45). –С. 25-30.
5. Abbate, A. Alterations in the Interleukin-1/Interleukin-1 Receptor Antagonist Bal-ance Modulate CardiacRemodelingfol-lowing Myocardial Infarction in the Mouse/ A. Abbate, F.N. Salloum, B.W. Van Tassell // PLoS One. –2011. –Vol.6, No11. –Р. e27923.
6. Москалев А. В., Рудой А. С., Апчел А. В. Характеристика отдельных иммунологических аспектов атерогенеза. Вестник Российской Военно-медицинской академии. 2017;1(57):205-9.5.
7. Kajdaniuk D, Marek B, Borgiel-Marek H, et al. Transforming growth factor β1 (TGFβ1) in physiology and pathology. Endokrynol Pol. 2013;64(5):384-96.
8. Брусенцов Д. А., Никулина С. Ю., Шестерня П. А., Чернова А. А. Ассоциация полиморфных вариантов RS1800470 гена трансформирующего ростового фактора β1 (TGF-β1) с тяжестью коронарного атеросклероза. Российский кардиологический журнал 2018; 23 (10)]. –С. 43-46.
9. Ken-ichi Aihara,1 Ya s u m a s a I k e d a , 2 Shusuke Yagi,3 Masashi Akaike,3 and Toshio Matsumoto. Transforming Growth Factor-β1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome. Cardiology Research and Practice. Volume 2011, Article ID 175381, 9 pages doi:10.4061/2011/175381.
10. Suthanthiran M., Gerber L. M., Schwartz J. E. et al., “Circulating transforming growth factor-β1 levels and the risk for kidney disease in African Americans,” Kidney International, vol. 76, no. 1, pp. 72–80, 2009.
11. Tashiro H., Shimokawa H., Sadamatu K. et al., “Prognostic significance of plasma concentrations of transforming growth factor-β in patients with coronary artery disease,” Coronar y Ar te r y D i s e a s e , vol. 13, no. 3, pp. 139–143, 2002.
12. Tashiro H., Shimokawa H., Sadamatu K. et al., “Prognostic significance of plasma concentrations of transforming growth factor-β in patients with coronary artery disease,” Coronar y Ar te r y D i s e a s e , vol. 13, no. 3, pp. 139–143, 2002.
13. Rosenkranz S., Flesch M., Amann K. et al., “Alterations of β-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β,” American Journal of Physiology, vol. 283, no. 3, pp. H1253–H1262, 2002.
14. Zacchigna L., Vecchione C., Notte A.et al., “Emilin1 links TGF-β maturation to blood pressure homeostasis,” Cell, vol. 124, no. 5, pp. 929–942, 2006.
15. Mancini, D. New methodologies to accurately assess circulating active transforming growth factor-p1 levels: implications for evaluating heart failure and the impact of left ventricular assist devices / D. Mancini, J. Monteagudo, M. Suárez-Fariñas, J. Bander, R. Varshney, J. Gonzalez, B. S. Coller, J. Ahamed // Transl Res. - 2018. - Vol. 192. -P. 15-29.
16. Zhang, F. Dang Y., Li Y., Hao. Q. Cardiac Contractility Modulation Attenuate Myocardial Fibrosis by Inhibiting TGF-P1/ Smad3 Signaling Pathway in a Rabbit Model of Chronic Heart Failure // Cellular Physiology and Biochemistry. - 2016. - Vol. 39. - P. 294-302.
17. Воронина Л.П., Шварц Ю Г,., Р.Б. Якушев, Е.А. Полунина, Анализ уровня трансформирующего фактора роста β1 при хронической сердечной недостаточности. Астраханский медицинский журнал. – 2018. - 13.3. - С. 9-15.
18. Izumiya Y., Hanatani S., Kimura Y. et al. Growth Differentiation Factor(15 is a useful prognostic marker in patients with heart
failure with preserved ejection fraction // Can. J. Cardiol. – 2014
Mar. – Vol. 30(3). – P. 338–344.
19. Бойко А.М., Шурупов В.С., Суслова Т.Е., Рябов В.В. Корреляционные связи сывороточного уровня трансформирующего ростового фактора β с клинико- инструментальными и лабораторными маркерами хронической сердечной недостаточности с сохраненной фракцией выброса левого желудочка. Сибирский журнал клинической и экспериментальной медицины. 2016;31(2):57-60. https://doi.org/10.29001/2073-8552-2016-31-2-57-60.
20. De Denus S., Lavoie J., Ducharme A. et al. Differences in biomarkers in patients witch heart failure with a reduced vs apreserved left ventricular ejection fraction // Can. J. Cardiol. – 2012 Jan(Feb. – Vol. 28(1). – P. 62–68. 11.
21. Mason J.M., Hacock H.C., Close H. et al. Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the Heart Failure in Care Homes (HFinCH) diagnostic accuracy study // PloS One. – 2013. – Vol. 8(1). – P. e535560.
22. Пушкарева А.Э, Хусаинова Р.И., Валиев Р.Р.. Изучение экспрессии рецептора ростового фактора и структуры гена трансформирующего фактора роста при сердечной недостаточности// Международный научно-исследовательский журнал.- 2016. - №9 (51). - URL: https://research-journal.org/archive/9-51-2016-september/izuchenie-ekspressii-receptora rostovogo-faktora-i-struktury-gena-transformiruyushhego-faktora-rosta-pri-serdechnoj-nedostatochnosti (дата обращения: 12.10.2022). - doi: 10.18454/IRJ.2016.51.046].
23. Rizokulovna A. D. Concomitant Conditions and Chronic Heart Failure //Central Asian Journal of Medical and Natural Science. – 2022. – Т. 3. – №. 5. – С. 87-96.
24. Dilnavoz A. R. Assessment of the expression of endothelial dysfunction in chronic heart failure in female patients //Assessment. –2021. –Т. 44. –No. 05.
2. Emelia J. Benjamin, Paul Muntner, Alvaro Alonso et.al. Heart Disease and Stroke Statistics – 2019 Update: American Association. Report From Heart https://doi.org/10.1161/CIR.0000000000000659. Circulation. 2019. Vol 139. No 10:e56–e528.).
3. Токмачев Р.Е., Будневский А.В., Кравченко А.Я. Роль воспаления в патогенезе хронической сердечной недостаточности. Терапевтический архив. 2016;88(9):106 110.
4. ВолковаС.Ю. Диагностические возможности ряда нейрогуморальных систем в определении систолической дисфункции левого желудочка у боль-ных ИБС с сердечной недостаточно-стью // Журнал Сер-дечная Недостаточность. –2008. –Т. 9, No1 (45). –С. 25-30.
5. Abbate, A. Alterations in the Interleukin-1/Interleukin-1 Receptor Antagonist Bal-ance Modulate CardiacRemodelingfol-lowing Myocardial Infarction in the Mouse/ A. Abbate, F.N. Salloum, B.W. Van Tassell // PLoS One. –2011. –Vol.6, No11. –Р. e27923.
6. Москалев А. В., Рудой А. С., Апчел А. В. Характеристика отдельных иммунологических аспектов атерогенеза. Вестник Российской Военно-медицинской академии. 2017;1(57):205-9.5.
7. Kajdaniuk D, Marek B, Borgiel-Marek H, et al. Transforming growth factor β1 (TGFβ1) in physiology and pathology. Endokrynol Pol. 2013;64(5):384-96.
8. Брусенцов Д. А., Никулина С. Ю., Шестерня П. А., Чернова А. А. Ассоциация полиморфных вариантов RS1800470 гена трансформирующего ростового фактора β1 (TGF-β1) с тяжестью коронарного атеросклероза. Российский кардиологический журнал 2018; 23 (10)]. –С. 43-46.
9. Ken-ichi Aihara,1 Ya s u m a s a I k e d a , 2 Shusuke Yagi,3 Masashi Akaike,3 and Toshio Matsumoto. Transforming Growth Factor-β1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome. Cardiology Research and Practice. Volume 2011, Article ID 175381, 9 pages doi:10.4061/2011/175381.
10. Suthanthiran M., Gerber L. M., Schwartz J. E. et al., “Circulating transforming growth factor-β1 levels and the risk for kidney disease in African Americans,” Kidney International, vol. 76, no. 1, pp. 72–80, 2009.
11. Tashiro H., Shimokawa H., Sadamatu K. et al., “Prognostic significance of plasma concentrations of transforming growth factor-β in patients with coronary artery disease,” Coronar y Ar te r y D i s e a s e , vol. 13, no. 3, pp. 139–143, 2002.
12. Tashiro H., Shimokawa H., Sadamatu K. et al., “Prognostic significance of plasma concentrations of transforming growth factor-β in patients with coronary artery disease,” Coronar y Ar te r y D i s e a s e , vol. 13, no. 3, pp. 139–143, 2002.
13. Rosenkranz S., Flesch M., Amann K. et al., “Alterations of β-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β,” American Journal of Physiology, vol. 283, no. 3, pp. H1253–H1262, 2002.
14. Zacchigna L., Vecchione C., Notte A.et al., “Emilin1 links TGF-β maturation to blood pressure homeostasis,” Cell, vol. 124, no. 5, pp. 929–942, 2006.
15. Mancini, D. New methodologies to accurately assess circulating active transforming growth factor-p1 levels: implications for evaluating heart failure and the impact of left ventricular assist devices / D. Mancini, J. Monteagudo, M. Suárez-Fariñas, J. Bander, R. Varshney, J. Gonzalez, B. S. Coller, J. Ahamed // Transl Res. - 2018. - Vol. 192. -P. 15-29.
16. Zhang, F. Dang Y., Li Y., Hao. Q. Cardiac Contractility Modulation Attenuate Myocardial Fibrosis by Inhibiting TGF-P1/ Smad3 Signaling Pathway in a Rabbit Model of Chronic Heart Failure // Cellular Physiology and Biochemistry. - 2016. - Vol. 39. - P. 294-302.
17. Воронина Л.П., Шварц Ю Г,., Р.Б. Якушев, Е.А. Полунина, Анализ уровня трансформирующего фактора роста β1 при хронической сердечной недостаточности. Астраханский медицинский журнал. – 2018. - 13.3. - С. 9-15.
18. Izumiya Y., Hanatani S., Kimura Y. et al. Growth Differentiation Factor(15 is a useful prognostic marker in patients with heart
failure with preserved ejection fraction // Can. J. Cardiol. – 2014
Mar. – Vol. 30(3). – P. 338–344.
19. Бойко А.М., Шурупов В.С., Суслова Т.Е., Рябов В.В. Корреляционные связи сывороточного уровня трансформирующего ростового фактора β с клинико- инструментальными и лабораторными маркерами хронической сердечной недостаточности с сохраненной фракцией выброса левого желудочка. Сибирский журнал клинической и экспериментальной медицины. 2016;31(2):57-60. https://doi.org/10.29001/2073-8552-2016-31-2-57-60.
20. De Denus S., Lavoie J., Ducharme A. et al. Differences in biomarkers in patients witch heart failure with a reduced vs apreserved left ventricular ejection fraction // Can. J. Cardiol. – 2012 Jan(Feb. – Vol. 28(1). – P. 62–68. 11.
21. Mason J.M., Hacock H.C., Close H. et al. Utility of biomarkers in the differential diagnosis of heart failure in older people: findings from the Heart Failure in Care Homes (HFinCH) diagnostic accuracy study // PloS One. – 2013. – Vol. 8(1). – P. e535560.
22. Пушкарева А.Э, Хусаинова Р.И., Валиев Р.Р.. Изучение экспрессии рецептора ростового фактора и структуры гена трансформирующего фактора роста при сердечной недостаточности// Международный научно-исследовательский журнал.- 2016. - №9 (51). - URL: https://research-journal.org/archive/9-51-2016-september/izuchenie-ekspressii-receptora rostovogo-faktora-i-struktury-gena-transformiruyushhego-faktora-rosta-pri-serdechnoj-nedostatochnosti (дата обращения: 12.10.2022). - doi: 10.18454/IRJ.2016.51.046].
23. Rizokulovna A. D. Concomitant Conditions and Chronic Heart Failure //Central Asian Journal of Medical and Natural Science. – 2022. – Т. 3. – №. 5. – С. 87-96.
24. Dilnavoz A. R. Assessment of the expression of endothelial dysfunction in chronic heart failure in female patients //Assessment. –2021. –Т. 44. –No. 05.
Published
2022-10-13
How to Cite
[1]
Rizokulovna, A.D. 2022. Chronic Heart Failure and Cytokines. International Journal on Integrated Education. 5, 10 (Oct. 2022), 87-91. DOI:https://doi.org/10.17605/ijie.v5i10.3554.
Section
Articles
In submitting the manuscript to the International Journal on Integrated Education (IJIE), the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with International Journal on Integrated Education (IJIE) agree to the following terms:
- Authors retain copyright and grant the International Journal on Integrated Education (IJIE) right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the International Journal on Integrated Education (IJIE) published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
1.png)
